CA-LIGHTBITS-LABS
Lightbits Labs , the pioneer and leader in NVMe™ over TCP (NVMe/TCP) software-defined storage, increased sales by more than 500 percent through a significant uptick in infrastructure as a service (IaaS), software as a service (SaaS), financial services, and video gaming customers.
Sales growth was fueled in part by the company’s strong partnerships, to which Intel was added in late September and also included new funding from Intel Capital . The partnership is designed to propel development of disaggregated storage solutions to solve the challenges of today’s data center operators who are craving improved storage efficiency and capacity utilization while maintaining compatibility with existing infrastructure without compromising performance and simplicity. This strategic partnership includes technical co-engineering, go-to-market collaboration, as well as the financial investment.
“In so many ways and for so many people 2020 was a very difficult year. Lightbits is fortunate that we were able to keep our employees safe through remote work, while also achieving and exceeding our goals for the year – including growing our customer base, enhancing our products, and expanding our partnerships and investors,” said Eran Kerzner, CEO. “We fully anticipate a strong surge in our sales throughout 2021.”
Last year, Lightbits announced significant product advancements, introducing LightOS™ 2.0 in June enabling full cloud-native persistent storage with high availability. The technological innovation solidified the company's position as a leader in scalable and efficient cloud-native storage that’s easy to consume for customers' private, hybrid, and edge cloud deployments. In December, the company released LightOS™ 2.1 that further enhances high-performance, scalability, and low latency so Lightbits’ customers can unleash hyperscale storage, but at a fraction of the cost of even the most advanced cloud storage offerings. As an example, Lightbits’ LightOS outperforms even the latest Amazon EBS io2 Block Express volumes with 5 times lower latency (200µs), 6 times the IOPS per volume (1.5M), twice the throughput per volume (8GB/s), 4 times larger volume size (256TB), and has features such as resizable volumes and multi-attach that are still roadmap items for io2 Block Express.
Through these advancements, Lightbits expanded the use cases for its patented solutions, including NVMe as a Service, as part of the IaaS umbrella. For financial services, use cases expanded to include database acceleration and Monte Carlo simulation. And under the SaaS umbrella, Lightbits LightOS gained traction as a high-performance replacement for Ceph.
In addition, Lightbits applied for five new patents that were accepted by the U.S. Patent Office, bringing the number of patents held by Lightbits to 20. The newly minted patents improve key functions within the NVMe/TCP storage architecture and help Lightbits protect its innovative approach to improving storage capacity utilization, reducing latency, and improving garbage collection features.
“With its blend of performance and high availability based around industry standards, NVMe/TCP offers a compelling value proposition for those needing extremely high performance in the composable block storage market,” said Eric Burgener, Research Vice President, Infrastructure Systems, Platforms and Technologies Group at IDC Research. “Lightbits Labs has significantly contributed to the NVMe/TCP standard and is continuing to improve upon the standard with its latest IP.”
Details on the new and existing Lightbits Labs patents can be found in the links below:
- 10,713,162: System and method for computer data peer to peer data transfers
- 10,684,964: System and method for reducing read latency in storage devices
- 10,642,733: System and method for memory interface load balancing
- 10,628,301: System and method for optimizing write amplification of non-volatile memory storage media
- 10,552,349: System and method for dynamic pipelining of direct memory access (DMA) transactions
Among the milestones, 2020 drove several notable industry recognitions including:
- Lightbits named to Storage 100 among 40 Coolest Software Defined Storage Vendors
- Lightbits listed as Top 10 Hottest Storage Startups
- Lightbits Wins 2020 4th China-Israel Innovation and Entrepreneurship Contest
- Lightbits Named Red Herring Top 100 Company Europe
- Lightbits Shortlisted as Most Promising Startup and Best Hybrid Cloud Solution
- Lightbits secures Bronze Stevie Award as Tech Startup of the Year-Software
Additional Resources:
- IDC Research: NVMe/TCP Enables the Democratization of Disaggregated NVMe-based Storage
- Lightbits Labs Hyperscale Storage for All Video
- LightOS 2.0 Product Overview: Software-Defined Composable Storage
- What New in LightOS 2.0? (blog)
- Kubernetes and LightOS: Performance, Persistence, Simplicity
- Apache Kafka and LightOS
About Lightbits Labs™
Lightbits Labs’ mission is to lead the cloud-native data center transformation by delivering scalable and efficient software defined storage that is easy to consume. Founded in 2016, Lightbits brings the agility of hyperscale storage to private clouds and edge clouds. The company pioneered NVMe/TCP so the solution is easy to deploy at scale, while delivering performance that is similar to local flash. Lightbits Labs is backed by strategic investors including Cisco Investments, Dell Technologies Capital, Intel Capital, and Micron, as well as top investors and VCs including Avigdor Willenz, Lip-Bu Tan, Marius Nacht, SquarePeg Capital, and WRVI Capital.
Visit www.lightbitslabs.com or contact us at info@lightbitslabs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005320/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
